Inverness Medical Innovations and BG Medicine to Develop Galectin-3 Test for Inverness’ Triage® Meter
26 Abril 2010 - 9:00AM
Business Wire
BG Medicine, Inc. announced today that it has entered into an
agreement with Inverness Medical Innovations, Inc. (NYSE: IMA)—a
global leader in enabling individuals to take charge of their
health at home through the merger of rapid diagnostics and health
management—for the development and commercialization of a
galectin-3 test for Inverness’ Triage® Meter Pro®. Galectin-3 is a
novel biomarker that may play a role in detecting the development
and progression of heart failure.
Under the agreement, Inverness will be responsible for the
development of the test in accordance with certain plans and
milestones, and Inverness and BG Medicine will collaborate in
support of development of the test and regulatory filings.
“We look forward to the development of additional heart failure
biomarker content, for use in conjunction with existing biomarkers,
to enhance the assessment of this complex and costly medical
condition,” said Ron Zwanziger, President and CEO of Inverness.
“BNP and galectin-3 each provide important independent
information about a patient's heart failure.” said Pieter
Muntendam, M.D., President and CEO of BG Medicine. “This business
opportunity was created by the natural complementarity of the two
tests.”
About Inverness Medical
Innovations
By developing new capabilities in near-patient diagnosis,
monitoring, and health management, Inverness Medical Innovations
enables individuals to take charge of improving their health and
quality of life. A global leader in rapid point-of-care
diagnostics, Inverness’ products, as well as its new product
development efforts, focus on infectious disease, cardiology,
oncology, drugs of abuse, and women’s health. Inverness is
headquartered in Waltham, Massachusetts.
About BG Medicine
BG Medicine is a life sciences company focused on the discovery,
development, and commercialization of novel diagnostics based on
biomarkers to improve patient outcomes and contain healthcare
costs.
Alere Inc. Common Stock (NYSE:IMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alere Inc. Common Stock (NYSE:IMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Alere Inc. Common Stock da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de BG Medicine, Inc.